Value
2.0/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Fwd P/E | 1.0 |
| PEG | 5.8 |
| Analyst target | 3.0 |
- ▸Forward P/E: 116.8x
- ▸PEG: 1.29
- ▸Expensive valuation
BLLN · Why this verdict
Why BillionToOne (BLLN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company has earned a wide economic moat designation, a Rule of 40 score of 89, and a near-perfect Piotroski F-score of 9/9, reflecting a competitively protected business with exceptional financial health. Quality breakdown | The Piotroski F-score remains at 8 or higher and the Rule of 40 stays above 60 for the next four reported periods, confirming durable quality. | →Stable |
| CounterA wide moat coexists with meaningful customer concentration risk; reliance on third-party payors means that coverage or reimbursement changes could compress margins even for a moat-protected business. | ||
Revenue growth of 84% year-over-year positions this company as the clear growth leader within its peer group, a pace that — if sustained — would justify a premium valuation over time. Growth breakdown | Revenue growth remains above 50% year-over-year for the next two reported quarters. | →Stable |
| CounterHyper-growth rates are structurally difficult to sustain as the revenue base expands; deceleration is nearly inevitable, and the current forward multiple above 100x provides no buffer if growth disappoints. | ||
With a forward price-to-earnings multiple above 100x and the stock sitting just below its near-term resistance target, implied upside is effectively exhausted and the setup does not offer a favorable risk-to-reward for new capital. Bear case | The forward multiple compresses below 50x as earnings growth outpaces stock price appreciation over 12 months, creating a more attractive entry point. | →Stable |
| CounterRare hyper-growth businesses with wide moats can sustain elevated multiples for extended periods if growth remains intact; the current premium may reflect the scarcity value of 84% top-line expansion. | ||
A high-severity customer concentration risk tied to third-party payors means that coverage decisions or reimbursement changes by a single category of counterparty could materially affect revenue. Risk breakdown | Revenue diversification reduces third-party payor reliance such that no single customer category represents more than 30% of revenue in the next annual filing. | →Stable |
| CounterConcentration in healthcare diagnostics is common and does not impair growth if the payer mix is stable; the wide moat and strong growth trajectory may insulate the business from payor-level negotiations. | ||
The company has earned a wide economic moat designation, a Rule of 40 score of 89, and a near-perfect Piotroski F-score of 9/9, reflecting a competitively protected business with exceptional financial health.
→StableQuality breakdown
- Expectation
- The Piotroski F-score remains at 8 or higher and the Rule of 40 stays above 60 for the next four reported periods, confirming durable quality.
CounterA wide moat coexists with meaningful customer concentration risk; reliance on third-party payors means that coverage or reimbursement changes could compress margins even for a moat-protected business.
Revenue growth of 84% year-over-year positions this company as the clear growth leader within its peer group, a pace that — if sustained — would justify a premium valuation over time.
→StableGrowth breakdown
- Expectation
- Revenue growth remains above 50% year-over-year for the next two reported quarters.
CounterHyper-growth rates are structurally difficult to sustain as the revenue base expands; deceleration is nearly inevitable, and the current forward multiple above 100x provides no buffer if growth disappoints.
With a forward price-to-earnings multiple above 100x and the stock sitting just below its near-term resistance target, implied upside is effectively exhausted and the setup does not offer a favorable risk-to-reward for new capital.
→StableBear case
- Expectation
- The forward multiple compresses below 50x as earnings growth outpaces stock price appreciation over 12 months, creating a more attractive entry point.
CounterRare hyper-growth businesses with wide moats can sustain elevated multiples for extended periods if growth remains intact; the current premium may reflect the scarcity value of 84% top-line expansion.
A high-severity customer concentration risk tied to third-party payors means that coverage decisions or reimbursement changes by a single category of counterparty could materially affect revenue.
→StableRisk breakdown
- Expectation
- Revenue diversification reduces third-party payor reliance such that no single customer category represents more than 30% of revenue in the next annual filing.
CounterConcentration in healthcare diagnostics is common and does not impair growth if the payer mix is stable; the wide moat and strong growth trajectory may insulate the business from payor-level negotiations.
TrendMatrix Research · core thesis
Engine thesis — one sentence
The company combines exceptional top-line growth of 84% year-over-year with a wide economic moat and a near-perfect balance sheet quality score, but with the stock sitting just below its near-term price target at a forward multiple above 100x, the current setup does not offer a compelling new entry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 2.9 |
| ROA | 3.0 |
| Gross margin | 10.0 |
| Op margin | 6.6 |
| Net margin | 3.5 |
| Current ratio | 5.0 |
| FCF quality | 5.1 |
| Moat | 7.9 |
| Rule of 40 | 9.5 |
| Piotroski F | 10.0 |
- ▸Earnings quality warning: 67% FCF/NI
- ▸Wide economic moat
- ▸Rule of 40: 89 (elite)
- ▸Strong Piotroski F-Score: 9/9
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 84% YoY
Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 2.6 |
- ▸Overbought bear rally (RSI 75)
- ▸Volume accumulation (rising OBV)
Sentiment
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.7 |
| Price target | 4.3 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (7.0) — signal dampened
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.3 |
- ▸Notable insider selling — $6,859,785 (0.124% of mkt cap)
Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.6 |
| quality rank | 5.7 |
| growth rank | 9.4 |
- ▸Industry growth leader
Technical
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.9 |
| support resistance | 0.5 |
| 52w position | 7.8 |
Risk (lower is worse)
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.4 |
| days to cover | 8.4 |
| volatility | 0.0 |
| put call | 3.0 |
| implied vol | 0.1 |
| max pain risk | 3.0 |
| debt equity | 8.9 |
- ▸Elevated put/call: 1.54
- ▸High IV: 80%
- ▸Above max pain $50
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:6.6>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:31d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.1=NEGATIVE
Warning (0)
none
Reward-to-Risk
-1.13
Upside
-16.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 10.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-1.1=NEGATIVE) reinforce the read. Current asymmetry R:R is -1.13 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 10.0, Momentum at 6.6, and Quality at 6.3; the weakest are Value at 2.0, Technical at 3.1, and Insider at 3.4. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -1.13 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Elite Quality Score
Trip ifPiotroski F-Score falls below 7 for 2 consecutive measurement periods, signaling deterioration in financial health.
- P2Industry Leading Revenue Growth
Trip ifRevenue growth falls below 40% year-over-year for 2 consecutive quarters.
- P3Expensive Valuation At Price Target
Trip ifForward P/E multiple compresses below 50x as earnings growth accelerates, indicating the expensive valuation concern has normalized.
- P4Customer Concentration Third Party Payors
Trip ifNo single customer category exceeds 25% of total revenue per the next annual filing, indicating meaningful revenue diversification.